JP6144201B2 - 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 - Google Patents
複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 Download PDFInfo
- Publication number
- JP6144201B2 JP6144201B2 JP2013546715A JP2013546715A JP6144201B2 JP 6144201 B2 JP6144201 B2 JP 6144201B2 JP 2013546715 A JP2013546715 A JP 2013546715A JP 2013546715 A JP2013546715 A JP 2013546715A JP 6144201 B2 JP6144201 B2 JP 6144201B2
- Authority
- JP
- Japan
- Prior art keywords
- urea
- quinolin
- pyridin
- pyran
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C1=C(*C(N(*)C(*I=**=*)=N*)=O)**N=C1C(N*)=O Chemical compound *C1=C(*C(N(*)C(*I=**=*)=N*)=O)**N=C1C(N*)=O 0.000 description 20
- GESLXCHQOQGEAN-SHMLVVSMSA-N CC1(CCOCC1)/C(/C)=N/C(/NC(NC(C(CN)=C)=C)O)=C\C Chemical compound CC1(CCOCC1)/C(/C)=N/C(/NC(NC(C(CN)=C)=C)O)=C\C GESLXCHQOQGEAN-SHMLVVSMSA-N 0.000 description 1
- OHHJJQZGSOYSCF-UHFFFAOYSA-N Cc(cc1Cl)cc2c1nccc2NC(Nc1nc(C2CCOCC2)ccc1)=O Chemical compound Cc(cc1Cl)cc2c1nccc2NC(Nc1nc(C2CCOCC2)ccc1)=O OHHJJQZGSOYSCF-UHFFFAOYSA-N 0.000 description 1
- URPIWIXRYAYPQV-UHFFFAOYSA-N Cc1ccc(C2CCOCC2)nc1NC(Nc1ccnc2c1cccc2Cl)=O Chemical compound Cc1ccc(C2CCOCC2)nc1NC(Nc1ccnc2c1cccc2Cl)=O URPIWIXRYAYPQV-UHFFFAOYSA-N 0.000 description 1
- FBWWNLBZZFVRQY-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2C(F)(F)F)Nc1cccc(C(F)(F)F)n1 Chemical compound O=C(Nc1ccnc2c1cccc2C(F)(F)F)Nc1cccc(C(F)(F)F)n1 FBWWNLBZZFVRQY-UHFFFAOYSA-N 0.000 description 1
- GWCWCWXMAZCRIV-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2=COCCC2)ccc1 Chemical compound O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2=COCCC2)ccc1 GWCWCWXMAZCRIV-UHFFFAOYSA-N 0.000 description 1
- VBISSAFCYVKVAC-UHFFFAOYSA-N O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2CCN(CC(F)F)CC2)ccc1 Chemical compound O=C(Nc1ccnc2c1cccc2F)Nc1nc(C2CCN(CC(F)F)CC2)ccc1 VBISSAFCYVKVAC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428478P | 2010-12-30 | 2010-12-30 | |
| US61/428,478 | 2010-12-30 | ||
| US201161521868P | 2011-08-10 | 2011-08-10 | |
| US61/521,868 | 2011-08-10 | ||
| PCT/EP2011/074272 WO2012089828A2 (en) | 2010-12-30 | 2011-12-30 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011851A Division JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501269A JP2014501269A (ja) | 2014-01-20 |
| JP2014501269A5 JP2014501269A5 (enExample) | 2015-02-19 |
| JP6144201B2 true JP6144201B2 (ja) | 2017-06-07 |
Family
ID=45524498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546715A Expired - Fee Related JP6144201B2 (ja) | 2010-12-30 | 2011-12-30 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
| JP2017011851A Pending JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017011851A Pending JP2017122089A (ja) | 2010-12-30 | 2017-01-26 | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9090592B2 (enExample) |
| EP (2) | EP3351543A1 (enExample) |
| JP (2) | JP6144201B2 (enExample) |
| KR (1) | KR101860297B1 (enExample) |
| CN (1) | CN103476766B (enExample) |
| AU (1) | AU2011351375B2 (enExample) |
| BR (1) | BR112013016928A2 (enExample) |
| CA (1) | CA2821863A1 (enExample) |
| IL (1) | IL226676A (enExample) |
| MX (1) | MX336346B (enExample) |
| NZ (1) | NZ611314A (enExample) |
| RU (1) | RU2623427C2 (enExample) |
| SG (2) | SG191789A1 (enExample) |
| WO (1) | WO2012089828A2 (enExample) |
| ZA (1) | ZA201304756B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017122089A (ja) * | 2010-12-30 | 2017-07-13 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008046919A2 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| EP3592731A4 (en) * | 2017-03-08 | 2020-10-07 | Cornell University | MALT1 INHIBITORS AND THEIR USES |
| RU2739489C2 (ru) * | 2018-03-06 | 2020-12-24 | Закрытое Акционерное Общество "Биокад" | Новые гетероциклические соединения как ингибиторы CDK8/19 |
| US20210393614A1 (en) * | 2018-10-17 | 2021-12-23 | Duke University | Quinone reductase 2 inhibitors for use as neuroprotective agents |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| ES3055187T3 (en) * | 2019-11-01 | 2026-02-10 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| DE69919707T2 (de) | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | Glycogen synthase kinase 3 inhibitoren |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| GT200100147A (es) | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| DZ3398A1 (fr) | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ES2307760T3 (es) | 2001-04-30 | 2008-12-01 | Aterna Zentaris Gmbh | Tratamiento de la demencia y enfermedades neurodegenerativas con dosis intermedias de antagonistas de lhrh. |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| DE60208630T2 (de) | 2001-05-11 | 2006-08-17 | Pfizer Products Inc., Groton | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| AU2002359162A1 (en) | 2001-12-21 | 2003-07-15 | Astrazeneca Ab | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| ATE536353T1 (de) | 2003-08-20 | 2011-12-15 | Vertex Pharma | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren |
| EP1689753A4 (en) | 2003-12-04 | 2010-07-07 | Glaxosmithkline Llc | NEW CHEMICAL COMPOUNDS |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| JP2008501696A (ja) | 2004-06-04 | 2008-01-24 | アンフォラ ディスカバリー コーポレーション | Ａｔｐ利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用 |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| JP2008505167A (ja) | 2004-07-05 | 2008-02-21 | アステックス、セラピューティックス、リミテッド | 医薬組成物 |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| UA92608C2 (en) | 2005-06-30 | 2010-11-25 | Янссен Фармацевтика Н.В. | Cyclic anilino - pyridinotriazines as gsk-3 inhibitors |
| EP1749523A1 (en) | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| UY29825A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| JP2009523845A (ja) | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
| WO2007089192A1 (en) | 2006-02-02 | 2007-08-09 | Astrazeneca Ab | Pharmaceutical use of 2-hydroxy-3- [5- (morpholin-4- ylmethyl) pyridine-2-yl] -1h- indole-5-carbonitrile as a free base or salts |
| WO2007120102A1 (en) | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
| EP1849785A1 (en) | 2006-04-28 | 2007-10-31 | Neuropharma, S.A. | N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| WO2008046919A2 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| CN101679353A (zh) | 2007-04-18 | 2010-03-24 | 阿斯利康(瑞典)有限公司 | 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法 |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| CN101790526A (zh) * | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 用作激酶抑制剂的5-杂芳基取代的吲唑化合物 |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| ES2418457T3 (es) * | 2008-04-24 | 2013-08-13 | Abbott Gmbh & Co. Kg | Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3) |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) * | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
-
2011
- 2011-12-29 US US13/339,884 patent/US9090592B2/en not_active Expired - Fee Related
- 2011-12-30 MX MX2013007702A patent/MX336346B/es unknown
- 2011-12-30 KR KR1020137020021A patent/KR101860297B1/ko not_active Expired - Fee Related
- 2011-12-30 SG SG2013050703A patent/SG191789A1/en unknown
- 2011-12-30 SG SG10201406098UA patent/SG10201406098UA/en unknown
- 2011-12-30 EP EP17206645.8A patent/EP3351543A1/en not_active Withdrawn
- 2011-12-30 BR BR112013016928-1A patent/BR112013016928A2/pt not_active IP Right Cessation
- 2011-12-30 JP JP2013546715A patent/JP6144201B2/ja not_active Expired - Fee Related
- 2011-12-30 AU AU2011351375A patent/AU2011351375B2/en not_active Ceased
- 2011-12-30 WO PCT/EP2011/074272 patent/WO2012089828A2/en not_active Ceased
- 2011-12-30 RU RU2013135477A patent/RU2623427C2/ru not_active IP Right Cessation
- 2011-12-30 NZ NZ611314A patent/NZ611314A/en not_active IP Right Cessation
- 2011-12-30 CN CN201180068418.0A patent/CN103476766B/zh not_active Expired - Fee Related
- 2011-12-30 CA CA2821863A patent/CA2821863A1/en not_active Abandoned
- 2011-12-30 EP EP11811357.0A patent/EP2658854B1/en not_active Not-in-force
-
2013
- 2013-05-30 IL IL226676A patent/IL226676A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04756A patent/ZA201304756B/en unknown
-
2015
- 2015-06-15 US US14/740,048 patent/US9540370B2/en not_active Expired - Fee Related
-
2017
- 2017-01-26 JP JP2017011851A patent/JP2017122089A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017122089A (ja) * | 2010-12-30 | 2017-07-13 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120172376A1 (en) | 2012-07-05 |
| US9540370B2 (en) | 2017-01-10 |
| EP2658854B1 (en) | 2017-12-13 |
| SG10201406098UA (en) | 2014-11-27 |
| US20150274724A1 (en) | 2015-10-01 |
| KR20140003518A (ko) | 2014-01-09 |
| JP2017122089A (ja) | 2017-07-13 |
| RU2623427C2 (ru) | 2017-06-26 |
| AU2011351375A1 (en) | 2013-06-20 |
| CN103476766B (zh) | 2016-08-10 |
| CA2821863A1 (en) | 2012-07-05 |
| ZA201304756B (en) | 2016-07-27 |
| RU2013135477A (ru) | 2015-02-10 |
| WO2012089828A2 (en) | 2012-07-05 |
| BR112013016928A2 (pt) | 2020-10-27 |
| KR101860297B1 (ko) | 2018-05-23 |
| JP2014501269A (ja) | 2014-01-20 |
| AU2011351375B2 (en) | 2016-08-04 |
| CN103476766A (zh) | 2013-12-25 |
| EP2658854A2 (en) | 2013-11-06 |
| MX336346B (es) | 2016-01-15 |
| US9090592B2 (en) | 2015-07-28 |
| MX2013007702A (es) | 2013-11-20 |
| NZ611314A (en) | 2015-06-26 |
| SG191789A1 (en) | 2013-08-30 |
| IL226676A (en) | 2015-08-31 |
| EP3351543A1 (en) | 2018-07-25 |
| WO2012089828A3 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2623427C2 (ru) | Гетероциклические соединения и их применение в качестве ингибиторов киназы-3 гликогенсинтазы | |
| JP5784001B2 (ja) | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのそれの使用 | |
| TW561154B (en) | Isothiazole derivatives useful as anticancer agents | |
| JP5998142B2 (ja) | 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用 | |
| JP5406030B2 (ja) | 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用 | |
| US12552785B2 (en) | Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof | |
| JP5756011B2 (ja) | グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物 | |
| US20240308980A1 (en) | Heteroaryl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| US20250026743A1 (en) | Heteroaryl-linked analogs as mglu5 negative allosteric modulators and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150917 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160415 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170127 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170411 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170510 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6144201 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |